Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Patterns of care: burr-hole cover application for chronic subdural hematoma trepanation.

Velz J, Vasella F, Akeret K, Dias SF, Jehli E, Bozinov O, Regli L, Germans MR, Stienen MN; CORRECT-SCAR study group.

Neurosurg Focus. 2019 Nov 1;47(5):E14. doi: 10.3171/2019.8.FOCUS19245.

PMID:
31675709
2.

69-year-old male with an intradural, extramedullary mass at T12-L1.

Velz J, Bellut D, Krayenbühl N, Winklhofer S, Rushing E, Frauenknecht K.

Brain Pathol. 2019 Sep;29(5):693-694. doi: 10.1111/bpa.12765. No abstract available.

PMID:
31441176
3.

Influence of the Intensive Care Unit Environment on the Reliability of the Montreal Cognitive Assessment.

Stienen MN, Geisseler O, Velz J, Maldaner N, Sebök M, Dannecker N, Rothacher Y, Schlosser L, Smoll NR, Keller E, Brugger P, Regli L.

Front Neurol. 2019 Jul 3;10:734. doi: 10.3389/fneur.2019.00734. eCollection 2019.

4.

Management of brainstem haemorrhages.

Wang SS, Yang Y, Velz J, Keller E, Luft AR, Regli L, Neidert MC, Bozinov O.

Swiss Med Wkly. 2019 Apr 5;149:w20062. doi: 10.4414/smw.2019.20062. eCollection 2019 Mar 25.

5.

A 32-Year-Old Women with an Intra- and Paraspinal, Extradural Mass at T10-T12.

Velz J, Neidert MC, Lauk O, Inci I, Bellut D, Rushing E.

Brain Pathol. 2019 Mar;29(2):309-310. doi: 10.1111/bpa.12708. No abstract available.

PMID:
30821031
6.

Analysis of safe entry zones into the brainstem.

Yang Y, van Niftrik B, Ma X, Velz J, Wang S, Regli L, Bozinov O.

Neurosurg Rev. 2019 Sep;42(3):721-729. doi: 10.1007/s10143-019-01081-9. Epub 2019 Feb 6.

PMID:
30726522
7.

Safety of resident training in the microsurgical resection of intracranial tumors: Data from a prospective registry of complications and outcome.

Vasella F, Velz J, Neidert MC, Henzi S, Sarnthein J, Krayenbühl N, Bozinov O, Regli L, Stienen MN.

Sci Rep. 2019 Jan 30;9(1):954. doi: 10.1038/s41598-018-37533-3.

8.

Repeated craniotomies for intracranial tumors: is the risk increased? Pooled analysis of two prospective, institutional registries of complications and outcomes.

Zattra CM, Zhang DY, Broggi M, Velz J, Vasella F, Seggewiss D, Schiavolin S, Bozinov O, Krayenbühl N, Sarnthein J, Ferroli P, Regli L, Stienen MN.

J Neurooncol. 2019 Mar;142(1):49-57. doi: 10.1007/s11060-018-03058-y. Epub 2018 Nov 24.

9.

Routinely Performed Serial Follow-Up Imaging in Asymptomatic Patients With Multiple Cerebral Cavernous Malformations Has No Influence on Surgical Decision Making.

Velz J, Stienen MN, Neidert MC, Yang Y, Regli L, Bozinov O.

Front Neurol. 2018 Oct 11;9:848. doi: 10.3389/fneur.2018.00848. eCollection 2018.

10.

Spontaneous Spinal Subarachnoid Hemorrhage with Development of an Arachnoid Cyst-A Case Report and Review of the Literature.

Velz J, Fierstra J, Regli L, Germans MR.

World Neurosurg. 2018 Nov;119:374-380. doi: 10.1016/j.wneu.2018.08.108. Epub 2018 Aug 24. Review.

PMID:
30149166
11.

Molecular and Clinicopathologic Heterogeneity of Intracranial Tumors Mimicking Extraskeletal Myxoid Chondrosarcoma.

Velz J, Agaimy A, Frontzek K, Neidert MC, Bozinov O, Wagner U, Fritz C, Coras R, Hofer S, Bode-Lesniewska B, Rushing E.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):727-735. doi: 10.1093/jnen/nly050.

PMID:
29924341
12.

The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.

Ehrhardt M, Craveiro RB, Velz J, Olschewski M, Casati A, Schönberger S, Pietsch T, Dilloo D.

J Cell Mol Med. 2018 Apr;22(4):2153-2161. doi: 10.1111/jcmm.13489. Epub 2018 Jan 29.

13.

The current management of spinal cord cavernoma.

Velz J, Bozinov O, Sarnthein J, Regli L, Bellut D.

J Neurosurg Sci. 2018 Aug;62(4):383-396. doi: 10.23736/S0390-5616.18.04305-9. Epub 2018 Jan 4.

14.

Isolated intracerebral Langerhans cell histiocytosis with multifocal lesions.

Velz J, Neidert MC, Bozinov O, Grotzer M, Kirschenbaum D, Rushing EJ.

Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26546. Epub 2017 Apr 24. No abstract available.

PMID:
28436595
15.

The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.

Craveiro RB, Ehrhardt M, Velz J, Olschewski M, Goetz B, Pietsch T, Dilloo D.

Oncotarget. 2017 Jul 18;8(29):46915-46927. doi: 10.18632/oncotarget.14911.

Supplemental Content

Support Center